People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Second Sight Medical Products Inc | — | Biotechnology | Series B | $130.9M | $807.7M | 2018 |
| eyeBrain Medical, Inc. | — | Biotechnology | Series C | $126.3M | $1.2B | 2017 |
William T. Link at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William T. Link on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Link | 2 | 11 |
| Eric Bednarski | 1 | 7 |
| Steve Kirby | 1 | 6 |
| Robert Greenberg | 1 | 6 |
| J. Andy Corley | 1 | 5 |
| Steve T Kirby | 1 | 3 |
| TOM FOGARTY | 1 | 3 |
| Tom Frinzi | 1 | 3 |
| Gregg Williams | 1 | 2 |
| Jonathan Will McGuire | 1 | 2 |
| Akhilesh Pathipati | 1 | 2 |
| Aaron Mendelsohn | 1 | 2 |
| Pierre Bertrand | 1 | 2 |
| John T. Blake | 1 | 2 |
| Bill T. Link | 1 | 1 |
| Tom Finzi | 1 | 1 |
| Das Narayandas | 1 | 1 |
| Danny Perales | 1 | 1 |
| Aric Plumley | 1 | 1 |
| Daniel Perales | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.